



21 March 2022
EMA/172225/20222
Human Medicines Division

Overview of (invented) names reviewed in February 2022 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 21-24 March 2022

	NRG meeting 15-16 Feb 2022		NRG meeting 28-29 Apr 2022		NRG meeting 28-29 Jun 2022		NRG meeting 20-21 Sep 2022		NRG meeting 15-16 Nov 2022		2022 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed (invented) names*	54	42									54	42
Justification for retention of (invented) name **	1	9									1	9

*Includes invented names, INN+MAH/TM and re-use applications.

**In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.



	NRG meeting 15-16 Feb 2022		NRG meeting 28-29 Apr 2022		NRG meeting 28-29 Jun 2022		NRG meeting 20-21 Sep 2022		NRG meeting 15-16 Nov 2022		2022 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Total number of objections raised	85	155									85	155
Similarity with other (invented) name	63	107									63	107
Conveys misleading therapeutic/pharmaceutical connotations	1	1									1	1
Misleading with respect to composition	0	0									0	0
Similarity with INN	7	29									7	29
Inclusion of INN stem	1	1									1	1
Unacceptable qualifiers	0	0									0	0
Conveys a promotional message	4	4									4	4
Appears offensive or has an inappropriate connotation	3	1									3	1
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0									0	0
Similarity between name of prodrug and related active substance	0	0									0	0
Others	6	12									6	12

See [Guideline on the Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure \(EMA/CHMP/287710/2014\)](#) for detailed explanations of criteria used.